Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ann Lab Med. 2024 Jan 1;44(1):92-96. doi: 10.3343/alm.2024.44.1.92. Epub 2023 Sep 4.
Limited data are available regarding the activity of SPR719, a derivative of benzimidazole, against diverse nontuberculous mycobacteria (NTM) species. We investigated the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of SPR719 against clinical NTM isolates, including clarithromycin- and amikacin-resistant strains. NTM isolates were obtained from patients with NTM-pulmonary disease caused by various NTM species, including complex, (subspecies and ), , and . Regardless of clarithromycin or amikacin resistance, the MIC and MBC values of SPR719 were comparable among these major pathogenic NTM species. In over 70% of the isolates, the MIC values were ≤2 μg/mL with MBC values of ≤4 μg/mL. The MIC and MBC values of were relatively lower than those of the other species with little difference between them, demonstrating the bactericidal properties of SPR719. The activity of SPR719 against major clinical NTM species suggests that SPR719 can serve as a novel treatment option for NTM-pulmonary disease.
关于苯并咪唑衍生物 SPR719 对各种非结核分枝杆菌（NTM）的活性，目前的数据有限。我们研究了 SPR719 对包括克拉霉素和阿米卡星耐药株在内的临床 NTM 分离株的最低抑菌浓度（MIC）和最低杀菌浓度（MBC）。NTM 分离株来自各种 NTM 引起的 NTM 肺病患者，包括 复合体、 （亚种 和 ）、 、 和 。无论克拉霉素或阿米卡星是否耐药，SPR719 的 MIC 和 MBC 值在这些主要致病性 NTM 种间相当。在超过 70%的分离株中，MIC 值为≤2μg/ml，MBC 值为≤4μg/ml。与其他种相比， 的 MIC 和 MBC 值相对较低，两者之间差异不大，表明 SPR719 具有杀菌作用。SPR719 对主要临床 NTM 种的活性表明，SPR719 可作为治疗 NTM 肺病的一种新的治疗选择。
